[go: up one dir, main page]

IN2014MN02487A - - Google Patents

Info

Publication number
IN2014MN02487A
IN2014MN02487A IN2487MUN2014A IN2014MN02487A IN 2014MN02487 A IN2014MN02487 A IN 2014MN02487A IN 2487MUN2014 A IN2487MUN2014 A IN 2487MUN2014A IN 2014MN02487 A IN2014MN02487 A IN 2014MN02487A
Authority
IN
India
Prior art keywords
pharmaceutical composition
adhesive free
present
excipient
granular
Prior art date
Application number
Inventor
Mathew Philip
Naresh Talwar
Original Assignee
Pharmascience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmascience Inc filed Critical Pharmascience Inc
Publication of IN2014MN02487A publication Critical patent/IN2014MN02487A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to an adhesive free pharmaceutical composition for the treatment of hepatitis B virus infections comprising at least one guanine based antiviral active pharmaceutical ingredient. More specifically the present invention concerns an oral pharmaceutical composition comprising: adhesive free granules comprising therapeutically effective amount of entecavir and at least one intra granular pharmaceutically acceptable excipient; at least one extra granular pharmaceutical excipient and optionally a moisture barrier coating. A method of manufacturing an adhesive free pharmaceutical composition is also disclosed.
IN2487MUN2014 2012-05-31 2013-05-28 IN2014MN02487A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA 2779052 CA2779052A1 (en) 2012-05-31 2012-05-31 Pharmaceutical composition of entecavir and process of manufacturing
PCT/CA2013/000517 WO2013177672A1 (en) 2012-05-31 2013-05-28 Pharmaceutical composition of entecavir and process of manufacturing

Publications (1)

Publication Number Publication Date
IN2014MN02487A true IN2014MN02487A (en) 2015-07-17

Family

ID=49672225

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2487MUN2014 IN2014MN02487A (en) 2012-05-31 2013-05-28

Country Status (9)

Country Link
US (2) US20150110869A1 (en)
EP (1) EP2854773B1 (en)
JP (1) JP6320371B2 (en)
KR (1) KR20150015500A (en)
CN (1) CN104363896A (en)
CA (2) CA2779052A1 (en)
HK (1) HK1208620A1 (en)
IN (1) IN2014MN02487A (en)
WO (1) WO2013177672A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6582000B2 (en) * 2014-06-20 2019-09-25 シーティーシー バイオ インコーポレイテッド Pharmaceutical preparation containing entecavir as active ingredient and method for producing the same
CN104473896B (en) * 2014-12-01 2017-04-19 东莞市金美济药业有限公司 Rapidly-disintegrating lamivudine tablets and preparation process thereof
JP7083760B2 (en) 2016-06-29 2022-06-13 テサロ， インコーポレイテッド How to treat ovarian cancer
MX2019011496A (en) 2017-03-27 2020-01-23 Tesaro Inc COMPOSITIONS OF NIRAPARIB.
SG11201908977SA (en) * 2017-03-27 2019-10-30 Tesaro Inc Niraparib formulations
KR20200058496A (en) 2017-09-26 2020-05-27 테사로, 인코포레이티드 Niraparib formulation
CN109550020A (en) * 2019-02-14 2019-04-02 任连智 A kind of pharmaceutical preparation that treating hepatitis B big and small three Yang and preparation method
CN110354129A (en) * 2019-08-19 2019-10-22 苏州扬厉医药科技有限公司 A kind of new drug pharmaceutical composition that treating hepatitis B and preparation method

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS51561B (en) * 2000-02-29 2011-08-31 Bristol-Myers Squibb Co. LOW DOSE FORMULATION OF ENTECAVIER AND USE
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
AU2003240213A1 (en) * 2002-06-24 2004-01-06 Ranbaxy Laboratories Limited Process for the preparation of robust formulations of valacyclovir hydrochloride tablets
US7905852B2 (en) * 2006-05-16 2011-03-15 Barbara Jennings-Spring Skin-contacting-adhesive free dressing
US20070281000A1 (en) * 2006-06-02 2007-12-06 Michael Fox Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof
CN101245068A (en) * 2007-02-14 2008-08-20 浙江医药股份有限公司新昌制药厂 Crystallization type entecavir, method of producing the same, pharmaceutical composition and uses thereof
WO2009106954A1 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable dosage forms of lamivudine and tenofovir
WO2009106960A2 (en) * 2008-02-27 2009-09-03 Aurobindo Pharma Limited Stable compositions of lamivudine, tenofovir and efavirenz
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
US20120308652A1 (en) * 2009-12-23 2012-12-06 Daniela Stumm Oral form of administration comprising entecavir
ES2524408T5 (en) * 2010-11-19 2022-04-25 Gilead Sciences Inc Therapeutic compositions comprising rilpivirine HCl and tenofovir disoproxil fumarate
EP2508172A1 (en) * 2011-04-06 2012-10-10 Zentiva, a.s. Stable and uniform formulations of entecavir and preparation method thereof
US20140315930A1 (en) * 2011-11-14 2014-10-23 Hetero Research Foundation Fast release solid oral compositions of entecavir
WO2013114389A1 (en) * 2011-12-21 2013-08-08 Mylan Laboratories Limited. Process for preparing solid oral formulations comprising low dose of entecavir

Also Published As

Publication number Publication date
JP2015521191A (en) 2015-07-27
EP2854773B1 (en) 2020-05-06
CN104363896A (en) 2015-02-18
WO2013177672A1 (en) 2013-12-05
CA2874779C (en) 2019-03-05
CA2874779A1 (en) 2013-12-05
HK1208620A1 (en) 2016-03-11
KR20150015500A (en) 2015-02-10
US20150110869A1 (en) 2015-04-23
EP2854773A1 (en) 2015-04-08
EP2854773A4 (en) 2016-01-27
US20190076366A1 (en) 2019-03-14
CA2779052A1 (en) 2013-11-30
JP6320371B2 (en) 2018-05-09

Similar Documents

Publication Publication Date Title
IN2014MN02487A (en)
AU2018256602A1 (en) Functionalized benzamide derivatives as antiviral agents against hbv infection
PH12018550148A1 (en) Hepatitis b antiviral agents
EA026667B9 (en) Pharmaceutical composition for treating hepatitis c virus
EA201592256A1 (en) DERIVATIVES OF IMIDAZOPIRROLIDINONE AND THEIR APPLICATION IN THE TREATMENT OF DISEASES
EA201592250A1 (en) Pyrazolopyrrolidine derivatives and their use in the treatment of diseases
ME02150B (en) Piperidinone derivatives as mdm2 inhibitors for the treatment of cancer
WO2011106729A3 (en) Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents
MD4736B1 (en) Polycyclic carbamoylpyridone compound and its pharmaceutical use
NZ739248A (en) Inhibitors of hepatitis c virus
WO2009123776A3 (en) Antiviral drugs for treatment of arenavirus infection
WO2013147649A3 (en) Inhibitors of the pi3k/akt/ikk/nf-kb signalling pathway, pharmaceutically acceptable salts thereof and compositions containing said inhibitors for the prophylaxis and treatment of viral diseases
MX2013001757A (en) Use of binders for manufacturing storage stable formulations
WO2017083304A8 (en) Therapeutic compositions for treatment of human immunodeficiency virus
EA201592255A1 (en) DERIVATIVES OF PYRAZOLOPIRROLIDIN-4-IT AS A BET INHIBITOR AND THEIR APPLICATION IN THE TREATMENT OF THE DISEASE
PH12012502083A1 (en) Manufacturing of active-free granules and tablets comprising the same
MY152951A (en) Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine, their preparation and their therapeutic application
WO2013022243A3 (en) Novel biphenyl derivative or a pharmaceutically acceptable salt thereof, and pharmaceutical composition for preventing or treating inflammatory diseases or autoimmune diseases comprising same as an active ingredient
HRP20221344T1 (en) New acetaminophen compound composition without side effect to liver
GR1008821B (en) Pharmaceutical composition comprising ivabradine hydrochloride and method for preparation thereof
GR1008228B (en) Pharmaceutical composition comprising a dual reuptake inhibitor and method for the preparation thereof
TR201310724A2 (en) Pharmaceutical formulati̇ons of linagliptin
EP2593460A4 (en) ANTI-VIRAL BENZYLAMIDE ANIMIRVENTS OF 4-OXO-4H-PYRIDO [L, 2-A] PYRIMIDINE-2-CARBOXYLIC ACID TO RADICALS NITROGEN IN POSITIONS 7 AND 9
PL3882244T3 (en) Compound, pharmaceutically acceptable salt or optical isomer thereof, method for preparing same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient
IN2011CH03893A (en)